Benzimidazole derivatives as modulators of IgE

Abstract

This invention relates to a family of benzimidazole analogs, which are inhibitors of the IgE response to allergens. These compounds are useful in the treatment of allergy, asthma, or any diseases where IgE is pathogenic.

1 . A pharmaceutical composition for treating an allergic reaction associated with increased IgE levels in a mammal comprising the following compounds:  
       
         
           
           
               
               
           
         
         wherein X and Y are independently selected from the group consisting of H, alkyl, alkoxy, aryl, substituted aryl, hydroxy, halogen, amino, alkylamino, nitro, cyano, CF 3 , OCF 3 . CONH 2 , CONHR and NHCOR 1 ;  
         wherein R is selected from the group consisting of H, CH 3 , C 2 H 5 , C 3 H 7 , C 4 H 9 , CH 2 Ph, CH 2 C 6 H 4 —F(p-), COCH 3 , CO 2 CH 2 CH 3 , aminoalkyl and dialkylaminoalkyl; and  
         wherein R 1  is a heterocyclic ring comprising a heteroatom or substituted heterocyclic ring comprising a heteroatom; and  
         wherein R 2  is selected from the group consisting of aryl, heteroaryl, thiophene, pyridyl, thiazolyl, isoxazolyl, oxazolyl, pyrimidinyl, substituted aryl, substituted heteroaryl, substituted thiophene, substituted pyridyl, substituted thiazolyl, substituted isoxazolyl, substituted oxazolyl, cycloaryl, cycloheteroaryl, quinolinyl, isoquinolinyl, substituted cycloaryl, substituted cycloheteroaryl, substituted quinolinyl, substituted isoqunolinyl, multi-ring cycloaryl, multi-ring cycloheteroaryl, benzyl, heteroaryl-methyl, substituted benzyl, substituted heteroaryl-methyl alkyl, dialkylaminoalkyl, cycloalkyl, cycloalkyl containing 1-3 heteroatoms, substituted cycloalkyl, substitute cycloalkyl containing 1-3 heteroatoms, multi-ring cycloalkyl, multiring cycloalkyl containing 1-3 heteroatoms, fused-ring aliphatic, fused-ring aliphatic containing 1-3 heteroatoms, cyclopropyl, substituted cyclopropyl, cyclobutyl, substituted cyclobutyl, cyclopentyl, pyrrole, piperidine, substituted cyclopentyl, cyclohexyl, substituted cyclohexyl, cycloheptyl, substituted cycloheptyl, bicycloheptyl, substituted pyrrole, substituted piperidine, bicyclooctyl, bicyclononyl, substituted bicycloalkenyl, adamantyl, and substituted adamantyl, heterocyclic ring, and substituted heterocyclic ring;  
         wherein at least one of R 1  and R 2  are aromatic groups or heteroaromatic groups; and  
         wherein R 1  and R 2  cannot both be phenyl groups.  
       
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein the substituent is selected from the group consisting of alkyl, aryl, CF 3 , CH 3 , OCH 3 , OH, CN, CONH 2 , CONHR, CONR 1 R 2 , COOR, and COOH.  
     
     
         3 . The pharmaceutical composition of  claim 1 , further comprising at least one additional ingredient which is active in reducing at least one symptom associated with said allergic reaction.  
     
     
         4 . The pharmaceutical composition of  claim 3 , wherein said at least one additional ingredient is selected from the group consisting of a short-acting β 2 -adrenergic agonist, a long-acting β 2 -adrenergic agonist, an antihistamine, a phosphodiesterase inhibitor, an anticholinergic agent, a corticosteroid, an inflammatory mediator release inhibitor and a leukotriene receptor antagonist.  
     
     
         5 . The pharmaceutical composition of  claim 1 , wherein the compound is selected from the group consisting of:  
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         6 . A method for treating an allergic reaction in a mammal wherein said reaction is caused by an increase in IgE levels comprising administering an IgE-suppressing amount of at least one compound of  claim 1 .  
     
     
         7 . The method of  claim 6 , further comprising administering in conjunction with at least one additional ingredient which is active in reducing at least one symptom associated with said allergic reaction.  
     
     
         8 . The method of  claim 7 , wherein said additional ingredient is selected from the group consisting of a short-acting β 2 -adrenergic agonist, a long-acting β 2 -adrenergic agonist, an antihistamine, a phosphodiesterase inhibitor, an anticholinergic agent, a corticosteroid, an inflammatory mediator release inhibitor and a leukotriene receptor antagonist.  
     
     
         9 . The method of  claim 6 , wherein the compound is selected from the group consisting of:  
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         10 . A method for treating asthma in a mammal comprising administering an IgE-suppressing amount of at least one compound of  claim 1 .  
     
     
         11 . The method of  claim 10  further comprising administering in conjunction with at least one additional ingredient which is active in reducing at least one symptom associated with said allergic reaction.  
     
     
         12 . The method of  claim 11 , wherein said additional ingredient is selected from the group consisting of a short-acting β 2 -adrenergic agonist, a long-acting β 2 -adrenergic agonist, an antihistamine, a phosphodiesterase inhibitor, an anticholinergic agent, a corticosteroid, an inflammatory mediator release inhibitor and a leukotriene receptor antagonist.  
     
     
         13 . The method of  claim 10 , wherein the compound is selected from the group consisting of:  
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         14 . A pharmaceutical composition for treating an allergic reaction associated with increased IgE levels in a mammal comprising the following compounds: Genus B,  
       
         
           
           
               
               
           
         
         wherein X and Y are independently selected from the group consisting of H, alkyl, alkoxy, aryl, substituted aryl, hydroxy, halogen, amino, alkylamino, nitro, cyano, CF 3 , OCF 3 . CONH 2 , CONHR and NHCOR 1 ;  
         wherein R is selected from the group consisting of H, CH 3 , C 2 H 5 , C 3 H 7 , C 4 H 9 , CH 2 Ph, CH 2 C 6 H 4 —F(p-), COCH 3 , CO 2 CH 2 CH 3 , aminoalkyl and dialkylaminoalkyl; and  
         wherein R 1  is selected from the group consisting of aryl, heteroaryl, thiophene, pyridyl, thiazolyl, isoxazolyl, oxazolyl, pyrimidinyl, substituted aryl, substituted heteroaryl, substituted thiophene, substituted pyridyl, substituted thiazolyl, substituted isoxazolyl, substituted oxazolyl, cycloaryl, cycloheteroaryl, quinolinyl, isoquinolinyl, substituted cycloaryl, substituted cycloheteroaryl, substituted quinolinyl, substituted isoqunolinyl, multi-ring cycloaryl, multi-ring cycloheteroaryl, benzyl, heteroaryl-methyl, substituted benzyl, substituted heteroaryl-methyl alkyl, dialkylaminoalkyl, cycloalkyl, cycloalkyl containing 1-3 heteroatoms, substituted cycloalkyl, substitute cycloalkyl containing 1-3 heteroatoms, multi-ring cycloalkyl, multiring cycloalkyl containing 1-3 heteroatoms, fused-ring aliphatic, fused-ring aliphatic containing 1-3 heteroatoms, cyclopropyl, substituted cyclopropyl, cyclobutyl, substituted cyclobutyl, cyclopentyl, pyrrole, piperidine, substituted cyclopentyl, cyclohexyl, substituted cyclohexyl, cycloheptyl, substituted cycloheptyl, bicycloheptyl, substituted pyrrole, substituted piperidine, bicyclooctyl, bicyclononyl, substituted bicycloalkenyl, adamantyl, and substituted adamantyl, heterocyclic ring, and substituted heterocyclic ring.